Use of Ceftazidime-Avibactam in the Treatment of Clinical Syndromes With Limited Treatment Options: A Retrospective Study

Abstract

BackgroundWith rising trends of multi-drug organism infections and the limited availability of new antimicrobials, management of such cases has become a hassle for the clinician. Ceftazidime-Avibactam (CEF-AVI) is evolving as an effective alternative to polymyxins in the management of Carbapenem-Resistant Organisms (CRO) infections. The Food and Drug Administration (FDA) has approved CEF-AVI in a restricted group of clinical syndromes where the drug could have potential use. ObjectiveThe goal of this study was to evaluate the clinical outcome in terms of 14-day all-cause mortality and clinical cure at seven days in patients on CEF-AVI. MethodologyA retrospective study was conducted on patients who received CEF-AVI in a period of one year in our hospital. Patients were included in the study if they have received CEF-AVI for more than one day of therapy (DOT) and samples from relevant sites have been sent for culture and sensitivity. Variables and outcomes were collected from the hospital information system and medical records. ResultsA total of 78 patients were included, 52 (66.7%) were started empirically on CEF-AVI while 26 (33.3%) were on targeted therapy. Out of the 78 patients, 43 patients had positive cultures among which 32 patients had Carbapenem-Resistant Enterobacteriaceae (CRE)/Carbapenem-Resistant Pseudomonas aeruginosa (CRPA) infection. The most common clinical syndrome in which the drug was used was occult sepsis (27/78; 34.6%) followed by primary bacteremia (20/78; 25.6%) and neutropenic sepsis (11/78; 14.1%). The clinical efficacy which was primarily assessed in terms of clinical cure was met for 55 (70.5%) patients. The 14-day mortality for the studies group was found to be 18 (23%). ConclusionThe analysis of results shows encouraging clinical cure rates and 14-day mortality rates in a subset of severe infections which has limited treatment options.

Sorption of Iodine on Biochar Derived from the Processing of Urban Sludge and Garden Waste at Different Pyrolysis Temperatures

“…The density of biochar under different reaction conditions was performed using a density bottle [46]. Accurate 2.0 g biochar samples in a density bottle mixed with a solution of ethanol were placed in a water bath at a constant temperature (20 °C).…”

The Protective Role of Cranberries and Blueberries in Oral Cancer

“…Oral cancer metastases spread primarily through the submandibular, cervical, and jugular lymph nodes. Distant metastasis spreads to the jaw and finally to the lungs, which compromises the health of the patient and has a higher risk of death [17][18][19][20]. Investigating and identifying the major mechanisms involved in oral carcinogenesis is therefore important.…”

Antibiotic prophylaxis in cardiac surgery: challenges and future perspectives

“…In contemporary times, a number of novel antibiotics including ceftazidime-avibactam and dalbavancin have been authorized for administration in clinical settings [37,38] . The antibiotics in question have exhibited effectiveness against bacteria that are resistant to multiple drugs, and possess the capability to improve the outcome of cardiac surgery patients [37,38] . Besides novel antimicrobial agents, inventive drug delivery systems could potentially mitigate the challenges associated with antibiotic utilization [39] in the context of cardiac surgery.…”

“…Beta-lactam antibiotics, which have been utilized for several decades, are currently encountering increasing resistance [36] . In contemporary times, a number of novel antibiotics including ceftazidime-avibactam and dalbavancin have been authorized for administration in clinical settings [37,38] . The antibiotics in question have exhibited effectiveness against bacteria that are resistant to multiple drugs, and possess the capability to improve the outcome of cardiac surgery patients [37,38] .…”